BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma

Authors

Karam Khaddour, Washington University School of Medicine in St. Louis
Tanner M. Johanns, Washington University School of Medicine in St. Louis
George Ansstas, Washington University School of Medicine in St. Louis

Journal

Melanoma Management

Publication Date

2021

Volume

8

Issue

2

First Page

MMT55

Document Type

Open Access Publication

DOI

10.2217/mmt-2020-0022

Rights and Permissions

Khaddour, K., Johanns, T. M., & Ansstas, G. (2021). BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma. Melanoma management, 8(2), MMT55. https://doi.org/10.2217/mmt-2020-0022. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Recommended Citation

Khaddour, Karam; Johanns, Tanner M.; and Ansstas, George, "BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma." Melanoma Management. 8, 2. MMT55 (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10394